ArticleMolecular and clinical oncology2026
A 4-cuproptosis-related lncRNA theragnostic signature predicts survival and immunotherapy response in patients with lung adenocarcinoma.
Article in Molecular and clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting copper death-related long non-coding RNAs: a novel strategy to overcome immunotherapy resistance in liver cancer.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung adenocarcinoma (LUAD), the most prevalent histological subtype of lung cancer worldwide, is associated with poor survival outcomes. Both cuproptosis and long non-coding RNAs (lncRNAs) demonstrate significant prognostic value and play emerging roles in LUAD immunotherapy. The aim of the present study was to identify a cuproptosis-related lncRNA signature for predicting survival and treatment response in patients with LUAD. Cuproptosis-related lncRNAs were screened from The Cancer Genome Atlas-LUAD cohort using Pearson correlation analysis (|R|>0.3, P<0.001) with 19 established cuproptosis genes. To establish a prognostic lncRNA signature for LUAD, univariate Cox regression followed by LASSO and multivariate Cox regression analyses were employed. Validation was performed using Kaplan-Meier survival analysis, principal component analysis, and functional enrichment analysis. A clinical nomogram integrating the signature with clinicopathological features was subsequently developed. The association of the signature with immunotherapy response and chemosensitivity was further assessed. Finally, reverse transcription-quantitative PCR confirmed the differential expression of cuproptosis-related lncRNAs in LUAD tissues. The results revealed that a 4-cuproptosis-related lncRNA signature (AC026355.2, AP000695.1, ARHGEF26-AS1 and AP005137.2) was established, demonstrating its utility as an independent prognostic factor for overall survival in patients with LUAD. In addition, the signature effectively differentiates between patients with different responses to immunotherapy. Finally, candidate compounds targeting the signature were identified. In conclusion, this cuproptosis-related lncRNA signature stratifies LUAD prognosis and immunotherapy response and provides a theragnostic tool for personalized therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.